by Raynovich Rod | Jan 20, 2017 | Clinical Diagnostics and Tools
Outlook and Issues for Application of NGS for Clinical Diagnostics We heard a few presentations on NGS solutions and still think it is an important growth market for clinical diagnostics in oncology, rare diseases transplant medicine and NIPT. Gene sequencing (NGS)...
by Raynovich Rod | Aug 18, 2016 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
Illumina (ILMN) Up 3 % to $174 on Buyout Speculation in Gene Sequencing Illumina, Inc. (ILMN) was up as much as 12 points earlier today on a rumored buyout from Thermo Fisher Scientific Inc. (TMO). Thermo bought another major player in sequencing Life Techologies for...
by Raynovich Rod | Jun 11, 2015 | 2024 Rayno Tools and Diagnostics Portfolio, Clinical Diagnostics and Tools
New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing sales and earnings...
by Raynovich Rod | Jan 19, 2015 | Biopharmaceuticals, Clinical Diagnostics and Tools
Seminar: Harnessing the Power of Next Gen Sequencing: The View from Industry 1/12/15 A panel of leading entrepreneurial R&D executives presented their outlook and issues on the future of Next Gen Sequencing (NGS), focusing on drug development and future clinical...
by Raynovich Rod | Jan 12, 2015 | 2024 Rayno Tools and Diagnostics Portfolio
Sequencing Remains Hot-Roche (RHHBY) Deal With Foundation Medicine (FMI) Worth $1.1B Targeted Oncology Therapy-Molecular information from pathways and biomarkers e.g. PDL-1 RNA based immunotherapy test Continuous monitoring of tumor specific information and molecular...
by Raynovich Rod | Oct 29, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-2 11/1/24…Market recovered from big losses yesterday with some buying in to XBI to the $99 level again.IBB remains choppy but up about 1% for the week. LOTS of green among SMID caps today: ADPT, CRBU, CRSP, DNLI, ILMN, EXEL, PACB,TEM etc. KUDOS to...
by Raynovich Rod | Sep 23, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Tools and Diagnostics Portfolio
Update-1 9/26/24… SMID CAP trading list movers today: ADPT, ARKG, CRMD, PACB,RXRX, TEM, TXG, TWST, with IBB up 1.09%. We will summarize complete list over the weekend. Adaptive Biotechnologies (ADPT), soars 22% on European certification. CorMedix...
by Raynovich Rod | Jul 22, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update-1 JY 24…Healthcare Stocks held up well during today’s technology sell-off. NASDAQ stocks took a big hit today with the QQQ down 3.59%.We can say it was caused by the Google earnings report as technology analysts tried to read beyond the actual...
by Raynovich Rod | May 28, 2024 | 2023-24 Life Science Portfolios, Life Science ETF's and Mutual Funds
Update: 6/7/24.,,Our model still looks good for experienced traders.Today for example GERON (GERN) soared 19% with approval of RYTELO for MDS associated anemia. We will summarize news from winning stocks over the weekend. XBI was weak today down about 1% to $91...
by Raynovich Rod | Mar 11, 2024 | 2023-24 Life Science Portfolios, 2024 Rayno Biopharmaceuticals Portfolio
Update-4 3/19..2:40p EDT..Stealth rally pre-FED day, call it an AI rally as all major indices are up. 10 year at 4.295%.If TSY yields stays down then small caps can follow: SMID Biotechs UP today are :CRBU, CBRX, CRMD,CYRX, PACB, SUPN etc with some buying in XBI at...
